Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
Delayed Nasdaq  -  04:00 2022-12-02 pm EST
182.35 USD   +0.48%
12/02Insider Sell: Moderna
MT
12/02Insider Sell: Moderna
MT
12/02Cornell University : Experimental vaccines offer long-term protection against severe COVID
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Moderna Adds New Role Ahead of Product Launches

09/29/2022 | 06:31am EST

By Will Feuer


Moderna Inc. is creating a new role on its executive committee as it prepares for the launch of multiple new products after the success of its Covid-19 vaccine.

The biotechnology company said Juan Andres, chief technical operations and quality officer, will step into a new role as president of strategic partnerships and enterprise expansion, effective Jan. 1. He will continue to serve on the executive committee and report to Chief Executive Stephane Bancel.

In his new role, Mr. Andres will focus on building out the company to support its growing pipeline, Moderna said.

Moderna said it will hire Jerh Collins, an executive at Novartis AG, to succeed Mr. Andres. Mr. Collins will join Moderna on Oct. 3 and will assume the role of chief technical operations and quality officer on Jan. 1, the company said. He will also serve on the executive committee and report to Mr. Bancel.

"I am very pleased that Juan will apply his leadership and experience to allow Moderna to scale in its next phase of growth. Juan's continued leadership will be critical as we prepare for several upcoming new product launches," Mr. Bancel said.


Write to Will Feuer at Will.Feuer@wsj.com


(END) Dow Jones Newswires

09-29-22 0831ET

Stocks mentioned in the article
ChangeLast1st jan.
COLLINS CO., LTD. -4.02% 19.1 End-of-day quote.24.84%
MODERNA, INC. 0.48% 182.35 Delayed Quote.-28.20%
NOVARTIS AG 0.05% 84.14 Delayed Quote.4.81%
All news about MODERNA, INC.
12/02Insider Sell: Moderna
MT
12/02Insider Sell: Moderna
MT
12/02Cornell University : Experimental vaccines offer long-term protection against severe COVID
AQ
12/01Transcript : Moderna, Inc. Presents at Piper Sandler 34th Annual Healthcare C..
CI
11/30Moderna exec says COVID trials improved diversity recruiting
RE
11/30Insider Sell: Moderna
MT
11/30Insider Sell: Moderna
MT
11/30Britain is little better prepared for future pandemics - Former UK vaccine chief
RE
11/28Insider Sell: Moderna
MT
11/28Insider Sell: Moderna
MT
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2022 19 089 M - -
Net income 2022 8 897 M - -
Net cash 2022 12 022 M - -
P/E ratio 2022 8,45x
Yield 2022 -
Capitalization 70 055 M 70 055 M -
EV / Sales 2022 3,04x
EV / Sales 2023 6,42x
Nbr of Employees 2 700
Free-Float 90,3%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Last Close Price 182,35 $
Average target price 211,25 $
Spread / Average Target 15,8%
EPS Revisions
Managers and Directors
StÚphane Bancel Chief Executive Officer & Director
Stephen Hoge President
James M. Mock Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.-28.20%70 055
IQVIA HOLDINGS INC.-22.83%40 441
LONZA GROUP AG-33.82%39 802
ALNYLAM PHARMACEUTICALS, INC.38.22%28 838
SEAGEN INC.-20.82%22 727
CELLTRION, INC.-12.12%18 382